The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.